Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 15/20 | 0.60 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.58 |
| ▸ | IGF1R | P08069 | 4/20 | 0.52 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3129628 | 0.96 | NUAK1 (0.60) | NTRK1NUAK1IGF1RNTRK3NTRK2 | |
| SCHEMBL3137277 | 0.82 | NUAK1 (0.56) | NTRK1NUAK1IGF1R | |
| SCHEMBL4696037 | 0.82 | NTRK1 (0.85) | NTRK1NUAK1IGF1R | |
| SCHEMBL27856020 | 0.81 | NTRK1 (0.71) | NTRK1NUAK1 | |
| SCHEMBL2566970 | 0.81 | NTRK1 (0.71) | NTRK1NUAK1 | |
| SCHEMBL3129694 | 0.80 | NTRK1 (0.85) | NTRK1NUAK1 | |
| SCHEMBL27872721 | 0.79 | NTRK1 (0.73) | NTRK1NUAK1 | |
| SCHEMBL2569980 | 0.79 | NTRK1 (0.73) | NTRK1NUAK1 | |
| SCHEMBL2490728 | 0.76 | NTRK1 (0.64) | NTRK1NUAK1IGF1RNTRK3NTRK2 | |
| SCHEMBL4070048 | 0.75 | IGF1R (0.60) | NTRK1NUAK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383268-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2015-09-02 | — | — | EP | disclosed |
| EP-2164490-A1 | PYRAZOLYL DERIVATIVES WITH ANALGESIC ACTIVITY AND THEREFORE USEFUL IN THE TREATMENT OR PROPHYLAXIS OF PAIN. | AstraZeneca AB (SE) | 2010-03-24 | — | — | EP | disclosed |
| EP-1853588-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008054292-A1 | PYRAZOLYL DERIVATIVES WITH ANALGESIC ACTIVITY AND THEREFORE USEFUL IN THE TREATMENT OR PROPHYLAXIS OF PAIN. | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
| US-20080108669-A1 | Use 541 | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108669-A1 | Use 541 | TRPV1, P2RX3, P2RX5 | NTRK1 3837/4885NUAK1 1374/4885IGF1R 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.